• MedlinePlus Genetics. What are genetic disorders? U.S. National Library of Medicine. https://medlineplus.gov/genetics
  • Doudna, J. A., & Charpentier, E. (2014). The new frontier of genome engineering with CRISPR-Cas9. Science, 346(6213). https://science.sciencemag.org
  • Collins, F. S., & Varmus, H. (2015). A new initiative on precision medicine.
    New England Journal of Medicine, 372, 793–795.
  • National Research Council. (2012). A Framework for K–12 Science Education.
    The National Academies Press.
  • European Commission. Ethics of genetic technologies and genome editing.
    https://ec.europa.eu
  • Ibáñez, M. B., & Delgado-Kloos, C. (2018). Augmented reality for STEM learning: A systematic review. Computers & Education, 123, 109–123.
  • Radu, I. (2014). Augmented reality in education: A meta-review. Educational Psychology Review, 26(2), 153–176.
  • Delightex. AR learning and assessment tools for education. https://www.delightex.com/edu
  • Cleveland Clinic. (2025). Genetic disorders: What are they, types, symptoms & causes. https://my.clevelandclinic.org/health/diseases/21751-genetic-disorders
  • Frangoul, H., Altshuler, D., Cappellini, M. D., Chen, Y. S., Domm, J., Eustace, B. K., Foell, J., de la Fuente, J., He, B., Kasper, R., Kernytsky, A., Lek, M., Mapara, M. Y., de Montalembert, M., Rondelli, D., Sharma, A., Sheth, S., Steinberg, M. H., Vichinsky, E., ... Corbacioglu, S. (2021). CRISPR-Cas9 gene editing for sickle cell disease and β-thalassemia. New England Journal of Medicine, 384(3), 252–260. https://doi.org/10.1056/NEJMoa2031054
  • Liang, P., Song, F., Xu, J., Zhang, X., Wang, Y., & Huang, J. (2024). CRISPR–Cas9 gene editing: Curing genetic diseases by repairing the genetic code. Journal of Nanobiotechnology, 22(1), Article 145.  https://doi.org/10.1186/s12951-024-02375-7
  • Russell, S., Bennett, J., Wellman, J. A., Chung, D. C., Yu, Z.-R., Tillman, A., Wittes, J., Pappas, J., Elci, O., Marshall, K. A., Coley, L., Reichert, M., George, L. A., Piazza, C., Venkatesh, A., & Maguire, A. M. (2017). Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: A randomised, controlled, open-label, phase 3 trial. The Lancet, 390(10097), 849–860. https://doi.org/10.1016/S0140-6736(17)31868-8
  • MedlinePlus Genetics. (n.d.). How are genetic conditions treated or managed?  https://medlineplus.gov/genetics/understanding/consult/treatment/
  • National Center for Biotechnology Information. (2020). Advances in CRISPR/Cas-based gene therapy in human genetic diseases.  https://pmc.ncbi.nlm.nih.gov/articles/PMC7150498/

AI-based tools (ChatGPT, Perplexity AI, and NotebookLM) were used to support content drafting, research synthesis, and organization of source materials during the development of this learning unit: